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Thioflavin T derivatives are used in positron-emission tomography (PET) studies to 
detect amyloid protein deposits in patients with Alzheimer disease. These tracers bind 
extensively to white matter, which suggests that they may be useful in studies of multiple 
sclerosis (MS), and that proteins resulting from proteolytic processing of the amyloid 
precursor protein (APP) may contribute to MS. This article reviews data from both clinical 
and preclinical studies addressing the role of these proteins, whether they are detected 
in CSF studies or using PET imaging. APP is widely expressed in demyelinated axons 
and may have a protective effect in MS and in experimental allergic encephalomyelitis in 
animals. Several mechanisms associated with this increased expression may affect the 
degree of remyelination in MS. Amyloid-PET imaging may help determine the degree of 
demyelination and provide information on the molecular changes linked to APP proteo-
lytic processing experienced by patients with MS.
Keywords: multiple sclerosis, amyloid PeT, biomarkers, white matter, amyloid precursor protein, amyloid, myelin 
basic protein, positron emission tomography
BACKGROUND
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS) 
that causes inflammatory lesions in the brain and spinal cord and ruptures the blood–brain barrier, 
leading to demyelination and axonal damage. In normal practice, MS is diagnosed based on clini-
cal symptoms, exclusion of other causes, and findings in cerebrospinal fluid (CSF) and magnetic 
resonance imaging studies. From a pathogenic point of view, MS is characterized by demyelination, 
which is attributed to inflammatory mechanisms and followed by neurodegeneration. In most 
cases, the disease initially presents a relapsing-remitting pattern (RRMS). Patients with this type of 
MS experience relapses followed by periods of partial or total recovery associated with incomplete 
remyelination. Remyelinating capacity decreases with time, especially in the secondary progressive 
form of the disease (1, 2).
Although β-amyloid protein (Aβ) is mainly linked to Alzheimer disease (AD), recent review 
articles suggest a connection between Aβ and MS (3, 4). One reason that led researchers to associ-
ate Aβ with MS was that white matter exhibits significant uptake of the PET tracers binding to 
this protein (5, 6), whereas white matter lesions associated with AD display lower uptake (7, 8). 
TABLe 1 | Studies of amyloid-related measurements in MS.
Reference Participants Measures Significant findings
(30) 23 cases (14 definite 
MS, 9 CIS)
CSF Aβ Increased Aβ
40 controls Aβ1–42
(31) 21 cases (CIS) CSF Aβ No differences in Aβ
21 controls Aβ1–40
Aβ1–42
(32) 100 cases MS
100 controls
67 cases systemic 
lupus erythematosus
CSF-BACE
CSF sAPPβ
CSF sAPPα
CSF Aβ
Aβ1–42
Decreased BACE
No differences in sAPPβ, 
sAPPα, Aβ
(33) 37 cases (RR) CSF sAPPβ
CSF Aβ
Aβ1–40
Aβ1–42
Decreased sAPPβ
Decreased Aβ10 controls
(34) 42 cases  
(35 RR, 7 CIS, 5 PP)
CSF Aβ Decreased Aβ
Aβ1–42
12 controls
(35) 77 cases (42 MS,  
10 NMO, 25 CIS)
CSF sAPPα No differences in  
sAPPα, AβCSF Aβ
21 controls Aβ1–42
(27) 2 cases RR PiB Lower uptake in lesions 
in T1 
(36) 65 cases  
(45 RR, 20 CIS)
CSF Aβ No differences in Aβ, 
although normal values 
were less frequent in RR 
patients than in controls.
83 controls
(37) 74 cases (32 RR,  
32 CIS, 10 PP)
CSF Aβ No differences in Aβ
Aβ1–42
74 controls
(38) 87 cases  
(54 RR, 33 SP)
28 controls
CSF sAPPα
CSF sAPPβ
CSF Aβ
Aβ X38
Aβ X40
Aβ X42
Aβ1–42
Decreased sAPα
Decreased sAPPβ
Decreased Aβ
Aβ peptides 
by mass 
spectrometry
(28) 12 cases PiB Lower uptake in white 
matter lesions
(39) 14 cases  
(13 SP, 1 PP)
CSF  
anti-oligomer 
monoclonal 
antibodies
Detected
(29) 12 cases  
(5 RR, 5 SP, 2 PP)
18F-florbetaben Lower uptake in white 
matter lesions than in 
normal-appearing white 
matter
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Myelin loss and breakdown of myelin basic protein (MBP) in 
AD patients and animal models of AD are associated with aging, 
the ApoE4 allele, or head injury, all of which are risk factors 
for AD, as well as with increases in Aβ peptides (9). Several 
pathology studies of AD have found decreased expression of 
MBP in the areas presenting Aβ deposition, and decreased Aβ 
deposition in white matter areas exhibiting greater expression 
of MBP. MBP has not been detected in amyloid plaques in AD 
patients (10, 11).
AMYLOiD-PeT iN MS
Positron-emission tomography using different amyloid trac-
ers [Pittsburgh Compound-B (PiB), florbetapir, florbetaben, 
flutemetamol, and others under study] can detect fibrillar Aβ 
deposits with high sensitivity and specificity; fibrillar Aβ is 
therefore considered a biomarker for AD along with levels of 
Aβ in CSF. This technique enables an in vivo pathological and 
molecular diagnosis, and it is currently included in clinical trial 
protocols for early detection of AD. Amyloid-PET findings 
have been proven to correlate well with fibrillar Aβ in neuro-
pathology studies (12). Assessing amyloid tracer uptake in gray 
matter is a technique for diagnosing AD and for differential 
diagnosis of neurodegenerative cognitive disorders. Most stud-
ies using amyloid-PET aim to assess this imaging technique’s 
utility for confirming AD diagnosis and predicting progression 
of mild cognitive impairment to dementia (13, 14). It is also 
used to diagnose other pathologies presenting with cogni-
tive impairment and which are not linked to Aβ exclusively 
(15–17). However, changes in amyloid-PET images may also 
be indicative of other neurological diseases (18). These tracers 
are thioflavin T derivatives and have been proven more specific 
than previous compounds based on Congo red and whose 
chemical basis was the styrylbenzene molecule or Chrysamine 
G, a derivative of Congo red (19). Thioflavin T analogs bind to 
amyloid fibrils, unlike Congo red derivatives, which also bind to 
tau fibrils. Several molecules have been developed by modifying 
the original structure, giving rise to other tracers that may have 
different affinities for certain tissues (20–23). Other molecules 
now being developed may have an even greater affinity for 
yelin (24).
Molecules currently in use derive from Pittsburgh Compound-A 
(25), an alternative name for BTA-1 (26), which resulted in PiB. 
This compound was used to develop three different radioligands: 
(1) SB1, which gave rise to 18F-florbetaben (AV1) and subse-
quently 18F-florbetapir (AV45); (2) 18F-flutemetamol; and (3) 
AZD2184, and subsequently AZD4694 (renamed NAV4694). At 
present, PiB, florbetaben, florbetapir, and flutemetamol have been 
tested in clinical trials, and the last three tracers are approved and 
available for clinical use.
Amyloid tracers detect decreased activity in black hole areas 
in T1-weighted MR images (27) and in white matter lesions in 
T2-weighted MR images (28, 29), in both the relapsing-remitting 
and the progressive forms of MS (Tables  1 and 2; Figure  1). 
These results showed that amyloid tracers bind extensively to 
white matter and that uptake decreases with demyelination. 
This inevitably leads us to question whether the usefulness of 
amyloid tracers in MS is due to their non-specific binding to 
white matter, or whether there may be a connection between Aβ 
and myelination.
FiGURe 1 | Amyloid-PeT and MRi image of a patient with RRMS using 
18F-florbetaben. Note the decreased uptake of the tracer in white matter 
lesions.
TABLe 2 | MRi correlations with measurements related to the amyloid cascade in MS.
Reference Participants Measure MRi-related finding
(35) 77 cases (42 MS, 10 NMO, 25 CIS) CSF sAPPα No correlation with MRI atrophy
CSF Aβ1–42
(34) 42 cases (35 RR, 7 CIS, 5 PP) CSF Aβ1–42 Aβ levels were lower in Gd + MS patients
No correlation was found with amyloid-β1–42 lesion load in T2 MRI sequences
(27) 2 cases (RR) PiB-PET Correlation between focal decreased amyloid uptake and T1 black holes
(29) 12 cases (5 RR, 5 SP, 2 PP) 18F-florbetaben No correlation between uptake in white matter lesions and total lesion volume in T2 images
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BiOMARKeRS OF APP PROTeOLYTiC 
PROCeSSiNG iN CSF iN  
PATieNTS wiTH MS
Different studies evaluating Aβ levels in CSF in patients with 
clinically isolated syndrome (CIS) or MS have yielded divergent 
results (30, 31, 36, 37). However, it seems that levels of interme-
diate products of proteolysis of the amyloid precursor protein 
(APP), such as soluble α-APP and β-APP, and one of the final 
products, Aβ1–42, are reduced in patients with both the RR and 
the primary progressive forms of MS (34, 35, 38, 39). Likewise, 
there is an inverse correlation between Aβ levels and presence of 
gadolinium-enhancing lesions. Low activity of β-site APP-cleaving 
enzyme 1 (BACE1), the enzyme participating in amyloidogenic 
APP proteolysis, has also been demonstrated in CSF in patients 
with MS (32). However, these data are challenging to interpret, 
since CSF Aβ levels fluctuate throughout the day. This biomarker 
is therefore difficult to assess and extrapolating changes observed 
in CSF to demyelinating plaques is not always possible (Table 1). 
Altered Aβ CSF levels seem to be linked to situations of lower 
activity as shown by gadolinium uptake in MR images. These find-
ings are not correlated with a greater degree of atrophy (Table 2).
eFFeCTS OF APP PROTeOLYTiC 
PROCeSSiNG iN MS
In patients with MS, β-APP accumulates in damaged axons (40). 
Experimental allergic encephalomyelitis (EAE), an experimental 
model for MS, is more severe in association with a genetic 
deletion of APP. Pathology studies have found increased Aβ 
expression in demyelinating plaques (41–43), which may even 
provide protection from damage (44); in fact, treatment with 
either Aβ42 or Aβ40 reduces motor paralysis and brain inflam-
mation and suppresses lymphocyte activation in animals with 
EAE. Similarly, decreased levels of pro-inflammatory cytokines 
and chemokines have been found in mice with EAE receiving 
Aβ peptides. Although these findings suggest that Aβ peptides 
are beneficial, we should not forget that they are neurotoxic and 
neuroinflammatory, and that APP proteolytic processing may 
provoke the opposite effect in demyelinated axons (45). This 
idea is consistent with studies describing increased Aβ42 levels in 
lesions and damaged axons. Several experimental studies report 
similar results: mice immunized with Aβ1–42 peptide experience 
symptoms whose presentation and pathological basis resemble 
those associated with EAE (46); Aβ injection in mice may damage 
the white matter (47) and induce oligodendrocyte death (48); and 
Aβ decreases the number of neurons in the subventricular zone 
and hippocampus and inhibits neurogenesis in the dentate gyrus 
of hippocampus, but not in the subventricular zone (49).
Amyloid precursor protein is extensively expressed in 
humans. Functions attributed to APP include neurite outgrowth 
and synaptogenesis, protein trafficking along axons, cell adhe-
sion, calcium metabolism, and signal transduction (50). Due to 
the activity of several successive proteolytic processes involving 
α- and β-secretases (depending on whether the process is amyloi-
dogenic), and subsequently γ-secretase, APP gives rise to soluble 
extracellular domains (sAPPα or sAPPβ) and the APP intracellular 
domain (AICD). Aβ is a protein with a great capacity to generate 
fibrils: it initially forms soluble monomers, and then oligomers, 
which remain soluble, until it ends up forming insoluble fibrils. 
Intracellular cascade of soluble peptides (β peptides, especially 
Aβ40 and Aβ42), which derive from APP proteolysis, may form 
oligomers and insoluble fibrillar deposits that become amyloid 
plaques (51). Another important fact is that APP is not an isolated 
protein, but rather one with two homologs: amyloid-like proteins 
1 and 2, or APLP1 and APLP2 (52). Although genetic deletion of 
APP in mice provokes minor impairment (53), triple-knockout 
mice show such problems as perinatal death, cranial abnormali-
ties, and cortical dysplasia (54, 55). The above suggests that APP 
family proteins fulfill essential yet partially redundant functions 
that can compensate for each other when several family members 
are present.
Although information on APP proteolytic processing in MS 
is scarce, we currently know that it is upregulated in damaged 
axons, which suggests that it may constitute a reliable marker 
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of axon demyelination (56). Increased APP expression has 
been observed following compression injury in spinal cord 
white matter in rats (57). In APP knockout mice, nodal length 
is greater, and sodium channels are clustered. Spinal cord 
myelin sheaths are thinner in both APP knockout and APP-
overexpressing transgenic mice (58). The potential impact of 
APP on MS may be related to coexpressing proteins. In fact, 
APP aggregates have been found in nodes of Ranvier, where 
APP expression colocalizes with tenascin-R, near the juxta-
paranodal potassium channels. Tenascin-R is an extracellular 
matrix glycoprotein of the tenascin family that is exclusive to 
the CNS. It acts on cell differentiation, migration, and adhesion. 
Tenascin-R expression increases following microglial activa-
tion (59). It is upregulated by platelet-derived growth factor 
(PDGF) and participates in oligodendrocyte differentiation 
and consequently in remyelination (60). Tenascin-R has been 
studied in connection with MS due to its role in myelination 
(61), and expression has been shown to be reduced in chronic 
demyelinating plaques and present in acute and subacute 
plaques. Some studies therefore suggest that Tenascin-R 
inhibits remyelination (62) and prevents repair (63). APP has 
also been associated with Tau and αB-crystallin proteins in MS 
lesions, and αB-crystallin (HspB5) and Aβ peptides appear 
to be beneficial in EAE (64). A small heat-shock protein, αB-
crystallin is highly immunogenic and associated with MS (65). 
It forms part of amyloid fibrils and improves EAE symptoms 
when administered systemically (66, 67). Other proteins that 
form part of amyloid fibrils are also beneficial, including Aβ A4, 
tau, amylin, and serum amyloid P (SAP). APP, αB-crystallin, 
and tau have been found in amyloid deposits in MS and they 
have demonstrated anti-inflammatory properties in MS animal 
models. The benefits of αB-crystallin are believed to be due to 
this protein’s ability to bind to pro-inflammatory proteins, and 
this ability increases in inflammatory processes. This activity 
takes place in a region of the molecule corresponding to the 
peptide that includes residues 73–92: in fact, this region alone 
is involved in EAE, and its activity is similar to that of the whole 
protein, which does not occur with other regions of the protein 
(68). This peptide can also form part of amyloid fibrils (69). 
At the same time, APP, αB-crystallin, SAP, and tau deficiencies 
in mice exacerbate EAE (70, 71). Furthermore, administration 
of the hexapeptide complex comprising the proteins included 
in amyloid fibrils rapidly decreases plasma levels of such pro-
inflammatory cytokines as IL-6 and IL-2 (72).
Another relevant enzyme is BACE1, a membrane-bound 
aspartyl protease (73). It is the only enzyme that directly breaks 
down APP to generate Aβ (74), and it accumulates in AD brains 
(75–79). BACE1-knockout mice also lack Aβ (80–82). Genetic 
deletion of BACE1 during development leads to hypomyelination 
in the central and peripheral nervous systems (83, 84), and the 
enzyme is necessary for sciatic nerve remyelination after an injury 
(85). The role of BACE1 in myelination may be explained by the 
fact that it processes neuregulin-1 and -3 (NRG1, NRG3) (86). 
Members of the NRG family of proteins are neurotrophic factors 
that act on ErbB receptors and trigger a biochemical cascade 
regulating several functions, including myelination. Decreased 
activity in this signaling pathway reduces myelin sheath thickness 
(87–90). This suggests that β secretase may play a crucial role in 
remyelination in MS.
On the other hand, Aβ peptides can trigger microglial 
activation (91–93). Microglial activation induced by Aβ in vivo 
is accompanied by decreased CD200 neuronal expression. The 
CD200 protein controls microglia and assists in inflammatory 
processes (94, 95).
PROTeiNS iNvOLveD iN APP PROTeOLYTiC 
PROCeSSiNG iN DeMYeLiNATiON
The role of APP and its homologs in demyelination may be due 
to APP proteolytic processing via substrates and enzymes. Both 
β- and γ-secretase are located in the lipid raft of the cell mem-
brane, which contains sphingolipids and cholesterol (96). This 
lipid composition of the membrane influences β- and γ-secretase 
activity (97–99). The potential role of lipid components in APP 
proteolytic processing has been extensively reviewed (100); Aβ 
production is modulated by sphingolipids. Demyelination leads 
to a release of myelin proteins (101): Nogo, myelin-associated 
glycoprotein, and oligodendrocyte myelin glycoprotein inhibit 
neuronal regeneration via Nogo and PirB receptors (102, 103), 
and MBP causes damage since it acts directly on the neuronal 
membrane (104). This protein, which has been regarded as 
one of the antigens for MS, performs many functions: it is 
involved in Aβ aggregation and inhibits Aβ fibril assembly 
(105), which affects Aβ levels. In experimental models, brain 
tissue inflammation followed by ischemia produces axonal and 
myelin damage with myelin aggregates that colocalize with 
APP and Aβ. In the 5XFAD mouse model, Aβ plaques were 
observed to colocalize with myelin aggregates (106). As shown 
by in vitro studies, MBP inhibits Aβ fibril assembly via residues 
1–64 (107), a fragment known as MBP1 (108). MBP1 has been 
proven to reduce pathological Aβ accumulation and clinical 
alterations in the 5XFAD mouse (109). This occurs in control 
animal models and has also been observed in models present-
ing mutant forms of Aβ (Dutch- and Iowa-type Aβ) that are 
responsible for cerebral amyloid angiopathy, in which MBP 
inhibits fibril formation (105). Although MBP1 may have a 
protective role in AD, it may be harmful in MS since it reduces 
amyloid fibril production, which favors the detrimental effect 
of Aβ peptides.
CONCLUSiON
Tracer uptake in white matter in amyloid PET imaging studies 
has raised questions about its utility as a biomarker of demyeli-
nation, specifically in white matter diseases such as MS. Several 
studies have aimed to determine how remyelination and MS are 
affected by APP and the proteins expressed via APP proteolytic 
processing, and whether amyloid-PET can provide an in  vivo 
molecular diagnosis of this process. Although further research 
on APP in MS is necessary, recent studies have demonstrated that 
(1) APP does play a role in MS; (2) APP proteolytic processing 
occurs as a result of demyelination, due to the action of myelin 
protein or lipid detritus; and (3) APP is involved in remyelination 
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